Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date
Yehenew A Ebstie,1,* Solomon M Abay,2,* Wondmagegn T Tadesse,3 Dawit A Ejigu4 1Department of Microbiology, Immunology and Parasitology, 2Department of Pharmacology, 3Department of Pharmacology and Clinical Pharmacy, School of Medicine, College of Health Sciences, Addis Ababa University, 4Department...
Saved in:
Main Authors: | Ebstie YA (Author), Abay SM (Author), Tadesse WT (Author), Ejigu DA (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and Efficacy of Tafenoquine for Plasmodium vivax Malaria Prophylaxis and Radical Cure: Overview and Perspectives
by: Markus MB
Published: (2021) -
Tafenoquine: A 2018 Novel FDA-Approved Prodrug for the Radical Cure of <i>Plasmodium vivax</i> Malaria and Prophylaxis of Malaria
by: Annie Mayence, et al.
Published: (2019) -
Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
by: James Watson, et al.
Published: (2018) -
Hypnozoite depletion in successive Plasmodium vivax relapses.
by: Rintis Noviyanti, et al.
Published: (2022) -
Population heterogeneity in Plasmodium vivax relapse risk.
by: Eva Stadler, et al.
Published: (2022)